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Abstract
Graves’ disease (GD) is an autoimmune pathology characterized by hyperthyroidism and the
presence of specific anti-thyroid antibodies. Neurological symptoms such as seizures, cognitive
impairment, and tremor can be observed during the course of GD, but more complex movement
disorders such as chorea and myoclonus are less frequent. The mechanisms underlying move-
ment disorders in GD are not fully understood. While some authors relate movement disorders
to thyroid dysfunction, others claim an autoimmune origin. We herein report a case involving a
60-year-old woman who presented with erratic, intricate movement disorders for which a med-
ical workup revealed GD. During the 2-year follow-up period, her neurological symptoms
evolved in parallel with her thyroid function, but not with her autoimmune anti-thyroid antibody
level. Her neurological symptoms completely disappeared when she became euthyroid.
We herein discuss the complicated clinicobiological relationship between thyroid function and
movement disorders. This relationship involves several factors, including the impact of radioac-
tive treatment. The present case emphasizes the importance of including thyroid function screen-
ing in the workup of unexplained movement disorders.
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Introduction
Graves’ disease (GD), the most frequent
cause of hyperthyroidism, is relatively fre-
quent (prevalence of approximately 1%) and
predominantly affects middle-aged women.
The autoimmune background of this endo-
crine pathology is now well recognized
to involve not only anti-thyroid-stimulating
hormone (anti-TSH) receptor antibodies
(TRAbs) but also less specific antibodies,
such as anti-thyroperoxidase (TPO) and
anti-thyroglobulin (Tg) antibodies.1,2 Two
types of TRAbs have been identified from
biological assays performed to assess the
effect of such antibodies on thyroid function:
stimulating TRAbs, which directly cause GD
and lead to hyperthyroidism and goiter, and
blocking TRAbs, which lead to hypothyroid-
ism. Nevertheless, the pathological mecha-
nisms of GD are probably complex because
the levels and actions of TRAbs do not per-
fectly correlate with thyroid function, and
both stimulating and blocking TRAbs coexist
in patients with GD and hypothyroidism.
TRAbs are even suggested to trigger a
switch from hyperthyroidism to hypothyroid-
ism and to predict the clinical outcome.2,3
The diagnosis of GD is straightforward and
involves the use of clinical and biological signs
of hyperthyroidism (low TSH and high
free T3 and T4 serum levels) combined with
specific immunological markers (elevated
TRAbs) and imaging markers (diffuse
goiter, high radioactive tracer uptake on scin-
tigraphy and radioiodine uptake at 24 hours,
and increased vascularity on Doppler
ultrasound).1
Tremor, muscle weakness, and cognitive
dysfunction are common neurologic
manifestations of hyperthyroidism; however,
only a few cases of chorea and myoclonus
have been reported in the literature. In gen-
eral, movement disorders disappear with nor-
malization of thyroid function, but whether
these movement disorders are a direct effect
of excess thyroid hormones or a consequence
of autoimmune dysfunction remains
unclear.4–9
We herein describe a 60-year-old patient
who was referred to our division for pre-
dominant left-limb complex dyskinesia,
including high-amplitude myoclonic jerks,
mild chorea, and associated postural
tremor. Etiological investigations of these
erratic involuntary movements led to a
diagnosis of hyperthyroidism due to GD.
Close clinical and biological follow-up for
2 years allowed us to demonstrate a clear
temporal relationship between the intensity
of these movement disorders and the serum
levels of thyroid hormones, but not between
the movement disorders and thyroid auto-
antibody concentrations. This observation
suggests that in the context of GD, thyroid
function is better correlated with movement
disorders than are autoantibodies.
Although the latter contribute to neurolog-
ical symptoms, their levels are determined
by several parameters with complex mech-
anisms,1,7 making it difficult to draw paral-
lels with clinical evolution. Finally, this case
report illustrates that thyroid function
should be systematically assessed in cases
of unexplained movement disorders.
Case report
The ear, nose, and throat division referred a
right-handed 60-year-old woman to our
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department for consultation regarding
unsteadiness in August 2014. Her main
complaint was the presence of progressive
involuntary movements that predominated
in her left upper and lower extremities and
had evolved during the past 5 years (oral
report by the patient without documenta-
tion in the endocrinologist’s reports). No
trigger or suppressing factor was evident,
but walking aggravated her symptoms and
caused rare falls. Nausea and positional
rotatory vertigo sometimes occurred, but
she had no associated hearing loss or tinni-
tus. She had ocular discomfort, headache,
palpitations, and weight loss without a
reduction in her food intake. She felt anx-
ious and nervous and could not sleep prop-
erly. She did not report fever, fatigue, joint
pain, or skin abnormalities. Her medical
history was remarkable for high blood pres-
sure treated by losartan 100 mg, chronic
back pain for which she took low doses of
oral tramadol, chronic diarrhea, and a dry
cough of unknown etiology. She was not
being treated with neuroleptic drugs. One
of her old medical reports from almost
1 year before our evaluation described a
thyroid nodule with strictly normal thyroid
function (Figure 1; month 0 [M0] in upper
graph) and no documented movement dis-
orders (however, when asked about the
accuracy of this old report, the patient con-
firmed already having had a mild but not
worrisome bilateral upper extremity
tremor). Her movement disorders worsened
with time and became so stigmatizing that
the patient was socially isolated and suf-
fered conflicting situations with her family
and friends (they incorrectly suspected that
she was an alcoholic and taking illic-
it drugs).
The initial neurological examination
showed mainly complex asymmetrical limb
movements, predominating on the left side
(Figure 1; M9 in the upper graph, corre-
sponding to the first visit with a clinical
evaluation during which Video 1 [V1] was
obtained; see also Video 1). These move-
ments consisted of a subtle postural high-
frequency tremor of approximately 7 Hz in
the horizontal axis (Figure 1; z axis on the
middle graphs), involving the upper left
limb in Video 1 and, later on, both upper
limbs as shown in Video 2. The tremor was
outweighed by high-amplitude lower limb
myoclonic jerky and irregular movements
that were visible at rest and with certain
postures (particularly when extending the
legs while sitting). The tremor was
enhanced when walking, thereby causing
unsteadiness. Additional discrete upper
limb choreic movements and akathisia
were possibly present (not shown in
Figure 1; see Video 1). The spiral test con-
firmed the overall erratic feature of the
movement disorders, especially on the left
side at the first visit (Figure 1; V1, left-most
graph in the middle of the figure and left
spirals in the lower part of the figure). No
other somatic neurological deficit was
observed (normal vestibular, cerebellar,
and sensory functions; no muscle strength
deficit, Parkinsonism, exophthalmos, or
cranial nerve abnormalities). There was no
evidence of cognitive impairment, and the
patient was calm and lucid,
although anxious.
Extended etiological investigations
showed no brain or spinal cord abnormali-
ties on magnetic resonance imaging. A stan-
dard electroencephalogram was normal, as
was a cerebrospinal fluid examination
(including the absence of 14-3-3 protein).
Blood tests revealed no infectious disease
(human immunodeficiency virus,
Treponema pallidum, and Borrelia burgdor-
feri serologies) or systemic autoimmune dis-
ease (rheumatoid factor, antinuclear
antibody, and lupus anticoagulant); para-
neoplastic antibodies were absent, and
there was no electrolytic disturbance. We
detected no micronutrient or vitamin defi-
ciency (B1, B9, B12, and E), no kidney or
liver dysfunction, and no stigma of systemic
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Figure 1. Clinical and biological follow-up of the movement disorders and thyroid function in the present
case. Upper graph: free T4 level (black squares, left y-axis) and thyroid-stimulating hormone (TSH) level (gray
diamonds, right y-axis) plotted against follow-up time (M, months). The x-axis shows the observation time
points in months, starting in December 2013 (M0) and ending in November 2015 (M23). The red stars above
the time points correspond to the performance of clinical evaluations. The four medical visits [labeled Visit 1
(V1), V2, V3, and V4, respectively] are shown below the corresponding time points, and videos were
recorded at these time points. The treatment steps are shown as red letters within circles according to the
initial treatment: D (oral anti-thyroid drugs), R (thyroid 131I radiation), and H (thyroid hormonal substi-
tution). Middle graphs: schematic representation of myoclonic movements (blue lines) and postural tremor
(red lines) on an arbitrary tridimensional axis system, oriented according to the patient’s left hand. They
correspond to the recorded videos at the medical visits, as shown by the black dashed-arrows. Bottom
figures: spiral tests performed at the initial and final neurological evaluations. The left figures correspond to
the patient’s left-hand drawings, and the right figures correspond to the right-hand drawings. Thyroid
function as assessed by TSH and free T4 was normal in December 2013 (M0). At the first neurological
evaluation in September 2014 (M9), TSH was undetectable in accordance with an elevated free T4 level, and
the movement disorders had the highest amplitudes. Myoclonic jerky movements were so intense that
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inflammation or rhabdomyolysis. The
only abnormalities were undetectable
TSH at 0.01mUI/L (reference range,
0.27–4.20mUI/L), high serum free T4 at
36 pmol/L (reference range, 10–24 pmol/L)
(Figure 1; M9, upper graph), and elevated
free T3 at 17.6 pmol/L (reference range,
2.8–4.2 pmol/L). Complementary tests
revealed high serum titers of TRAbs, anti-
TPO antibodies, and anti-thyroglobulin
antibodies (1.4U/L [reference range,
0.0–0.4U/L], 206 kUI/L [reference range,
0–16 kUI/L], and 140 kUI/L [reference
range, 0–100 kUI/L], respectively). The thy-
roid gland was diffusely enlarged (30-mL
volume) with augmented vascularity on
Doppler flow ultrasound (the volume of
the previously described nodule was pro-
portionally increased in this context).
Thyroid scintigraphy (123I) and radioactive
iodine (RAI) uptake consistently showed
intense and homogenous tracer uptake
into both thyroid lobes (15.0% at 3 hours
and 33.5% at 24 hours for RAI).
We therefore diagnosed hyperthyroidism
due to GD. Upon reconsidering the
patient’s clinical course, we determined
that general symptoms of thyrotoxicosis
(anxiety, weight loss, palpitation, headache,
high blood pressure, ocular discomfort, and
tremor)1 had been present but were over-
looked, most probably because the erratic
involuntary movements misled the diagno-
sis toward other neurological diseases.
The patient benefited from carbimazole treat-
ment (Figure 1; D (drugs), upper graph of
figure) that unfortunately had to be stopped
due to severe myalgia but was rapidly
switched to propylthiouracil (Figure 1; still
D in upper graph). However, the propylth-
iouracil was also stopped because of adverse
effects. Nevertheless, significant clinical ame-
lioration was noticed in parallel with her
improved thyroid function (Figure 1; V2 at
M12 in the upper graph; second-to-left
middle graph) (Video 2) during this short
anti-thyroid treatment, whereas slight deteri-
oration in the free T4 level occurred when the
oral drugs were definitively stopped. Her
heart rate was 80 and 85 beats per minute
in November 2014 (Figure 1; M11). Shortly
thereafter, the patient was re-evaluated and
showed no clinical or biological evidence of
myositis or any other muscular or systemic
disorder (normal creatine kinase and inflam-
matory biomarkers, no liver dysfunction,
no eosinophilia). Thus, radioiodine therapy
could be initiated (Figure 1; R at M13,
upper graph). The free T4 level subsequently
normalized (Figure 1; M14) before iatrogenic
hypothyroidism occurred (Figure 1; M15).
Under thyroid hormonal substitution
(Figure 1; H initiated at M15, upper graph),
the free T4 level returned to normal and the
TSH level decreased in parallel, with further
improvement in her movement disorder
(Figure 1; V3 at M17 in the upper graph
and third-to-left middle graph) (Video 3).
Figure 1. Continued.
tremor was difficult to visualize. Both involuntary movements predominated in the horizontal and vertical
axes. The spiral test confirmed left-side predominance and the erratic characteristics of the movement
disorders. After oral anti-thyroid treatment (D), the patient’s thyroid function slightly improved in parallel
with both movement disorders (V2 at M12). Reduction of the myoclonic movement amplitude made the
tremor more apparent at this point. Thyroid function further deteriorated after anti-thyroid treatment was
stopped; radioactive iodine treatment (R) then led to significant lowering of the free T4 level with subse-
quent TSH elevation, until hypothyroidism developed (M15). After thyroid hormonal substitution (H),
thyroid function began to normalize (M17 to M23), while the movement disorders progressively decreased
(tremor was the last to disappear). At the last evaluation (M23), no abnormal movements were present and
the free T4 level was normal (TSH was close to the reference values). The last spiral test also reflected this
marked clinical and biological amelioration.
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From February 2015 to August 2015
(Figure 1; M14–M20), her heart rate
remained stable at 65 beats per minute. At
the end of the observation period, her move-
ment disorders had completely disappeared,
her free T4 level remained within the refer-
ence range, and her TSH level had almost
normalized; additionally, the spiral test was
now almost correctly performed on the left
and right sides (Figure 1; V4 at M23 in the
upper graph; right-most middle graph; right
spirals at the bottom of the figure) (Video 4).
This case study was performed in accor-
dance with local and international ethical
guidelines, and the patient provided oral
and written informed consent for the pre-
sent publication.
Discussion
The patient described in this case report
had progressive irregular and involuntary
limb movements, including myoclonic jerk
and chorea mixed with high-frequency pos-
tural tremor. The workup only revealed
suppressed TSH and high free T4 and free
T3 levels associated with increased TRAbs.
Diffuse goiter with increased vascularity
and homogenously elevated RAI uptake
after 24 hours further confirmed the diagno-
sis of GD.1 Because the extensive etiological
workup was otherwise negative, including
tests for systemic diseases associated with
similar neurological disorders,10,11 we
assumed the presence of a causal relation-
ship between the patient’s movement disor-
ders and GD.
The involuntary movements observed in
our patient were more complex than the
usual tremor expected for hyperthyroid-
ism12 because they included myoclonic
jerky limb shaking and discrete choreic
movements. During careful observation of
the patient at the initial neurological exam-
ination, we finally identified the more typi-
cal high-frequency tremor in the left upper
limb. As the myoclonic jerks disappeared,
the tremor became more evident in both
upper limbs. Apart from tremor, chorea is
more frequently mentioned than myoclonus
(which predominated in our patient) in the
context of GD, but both have been
reported.1,4–9 These findings led us to con-
clude that the movement disorders observed
in our patient were compatible with
hyperthyroidism.13
The 2-year follow-up showed that the
patient’s movement disorders evolved in
parallel with her thyroid function; i.e.,
their highest amplitude coincided with the
worst hyperthyroid state (undetectable TSH
and highest free T4 levels). Similarly, as her
thyroid function improved, the amplitude
of the movement disorders decreased until
they disappeared upon normalization of the
thyroid hormone levels.4–9 In addition, the
nature of the anti-thyroid treatment (anti-
thyroid drugs or RAI therapy) did not
influence the patient’s clinical responsive-
ness. During the course of treatment, the
patient developed post-RAI hypothyroid-
ism. One could therefore question the role
of hypothyroidism in the patient’s involun-
tary movements because both hyperthy-
roidism and hypothyroidism are associated
with similar movement disorders.10
However, we noticed that the involuntary
movements were not modified either with
or without hypothyroidism. Taken togeth-
er, these observations suggest a role of
thyroid hyperfunction in the occurrence of
movement disorders.
In hyperthyroidism, beta-adrenergic
stimulation is incriminated as a mechanism
leading to tremor and probably also to
chorea; indeed, both respond well to beta-
blockers.14 Alternative mechanisms under-
lying chorea and myoclonus, although not
fully elucidated,4,7 could involve a direct
effect of thyroid hormones on the basal
ganglia,5 thus supporting our hypothesis
of a causal relationship between excessive
serum thyroid hormone levels and move-
ment disorders. Conversely, autoimmune
Delhasse et al. 1383
mechanisms have been proposed as an
explanation for these two unusual move-
ment disorders in GD.1,7 Our patient’s neu-
rological symptoms appeared well ahead of
her thyroid dysfunction, and the serum
levels of all thyroid autoantibodies were
high at the initial evaluation, supporting
this hypothesis.4,7,15 However, despite the
disappearance of neurological symptoms
at the end of treatment, her anti-TPO anti-
body level remained steadily high, and her
TRAbs even increased up to five fold.
Several other observations should be
considered to explain this discrepancy.
Anti-TSH receptors, as well as anti-TPO
antibodies, often increase and remain high
for long periods after RAI treatment,1 espe-
cially in patients who develop post-iodine
hypothyroidism,16 as did our patient. This
is a reflection of the intensity and duration
of the thyroid’s autoimmune inflammatory
response or gland destruction in reaction to
radioiodine therapy rather than a sign of
treatment efficiency.3,16 Moreover, pub-
lished reports have indicated that during
the disease course, the levels and actions
of TRAbs do not perfectly parallel the
TSH profile. In addition, our measurements
did not differentiate between blocking and
stimulating TRAbs,3 which are suggested to
trigger the switch from hyperthyroidism to
hypothyroidism and vice versa.2,3 Thus, it
appears that the levels of thyroid autoanti-
bodies are determined by many factors
(pathological and therapeutic) and there-
fore cannot be considered as biomarkers
of the neurological outcome in patients
with GD, even if autoimmunity at least par-
tially regulates the clinical evolution in
such cases.
In summary, a direct effect of excessive
thyroid hormone levels is the most plausible
mechanism explaining the genesis and dis-
appearance of movement disorders in our
patient, although we cannot completely
exclude contribution of the autoimmune
background of GD.
Although such movement disorders
have been reported in patients with hyper-
thyroidism,13,14 a functional origin must
also be considered because of the complex-
ity of such movements.17 Entrainment and
distractibility could not be excluded in our
case because the patient was not challenged
by complex mental tasks and activities
during the clinical examination. However,
the existence of tremor in more than one
axis (i.e., in the vertical and horizontal
axes) and variability in the amplitude and
axes in the different tasks in the first neuro-
logical evaluation supported a functional
component.18–20 Nevertheless, the following
observations argue against a functional
tremor. First, the tremor did not suddenly
appear and was not triggered by a stressful
life event. Second, no somatization was
reported in the patient’s medical history,
and the tremor’s high frequency remained
more or less stable throughout consecutive
clinical examinations. Finally, the parallel
evolution of the tremor and other move-
ment disorders with thyroid function, as
well as their occurrence well before the
patient developed anxiety (in the context
of hyperthyroidism), contends a functional
hypothesis. In summary, although it is
difficult to rule out functional tremor with
certainty and distinguish tremor due to
hyperthyroidism, both could coexist in this
clinical picture.
Our patient exhibited myalgia, an
extremely rare complication of both of the
oral anti-thyroid treatments,21,22 which
vanished after stopping the treatment. The
normal clinical and blood test results after
disappearance of the muscle pain prevented
us from hypothesizing as to the underly-
ing mechanisms.
In conclusion, our patient presented rare
and handicapping movement disorders that
were presumably due to hyperthyroidism
in the context of GD, although we could
not completely exclude a functional compo-
nent. During the 2-year clinical and
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biological follow-up, we documented that
the neurological symptoms were well corre-
lated with the thyroid hormone levels rather
than with markers of autoimmunity (prob-
ably influenced by many other parameters).
Similar movement disorders are associated
with autoimmune Hashimoto’s encephalop-
athy and respond well to corticosteroids23,24
(even if elevation of anti-TPO antibodies
does not seem to be linked to the severity
of neurological symptoms23). In contrast,
our case allows for consideration of non-
autoimmune mechanisms at the origin of
such a complex dyskinetic syndrome. This
case report emphasizes that inexplicable
movement disorders warrant thyroid func-
tion evaluation, especially because treating
thyroid dysfunction such as hyperthyroidism
efficiently alleviates neurological symptoms.
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